Role of Midkine in Predicting Malignancy in Patient with Solitary Thyroid Nodule

Main Article Content

Nesma A. Ibrahim
Ahmed M. Hamam


Background: Solitary thyroid nodules are a common clinical problem. None of sonographic features is sufficient to discard or detect malignancy efficiently. Midkine is a novel heparin-binding growth factor, plays critical roles in carcinogenesis. In this study, we aimed to evaluate serum midkine levels in patients with solitary thyroid nodules to predict malignancy.

Methods: A total of 100 patients who had solitary thyroid nodules were enrolled in the study. Serum midkine levels were measured. Fine needle aspiration cytology was done to all nodules (25 suspicious/ malignant and 75 benign).

Results: Serum midkine levels were significantly higher in patients who had nodules with the following sonographic features; hypoechoic nodules compared to isoechoic and hyperechoic nodules (P=0.024), nodules with microcalcification compared to nodules with macrocalcification or without calcification (P = 0.011), nodules with irregular borders compared to nodules with regular borders (P = 0.014) and nodules more than 2 cm in length than shorter ones (P = 0.011). Serum midkine levels were also higher in nodules with absent halo compared to those with clear halo but with no significant difference (P = 0.660). Also, levels of serum medikine were significantly higher in suspicious/ malignant nodules than in benign nodules (P < 0.001).

Conclusion: Serum midkine can predict malignancy in solitary thyroid nodule and also well correlated with sonographic features of thyroid nodules. We suggest that midkine levels may serve as a novel biochemarker in association with sonographic features in evaluation of solitary thyroid nodules.

Midkine, thyroid nodule

Article Details

How to Cite
Ibrahim, N., & Hamam, A. (2019). Role of Midkine in Predicting Malignancy in Patient with Solitary Thyroid Nodule. Journal of Cancer and Tumor International, 9(2), 1-10.
Original Research Article


Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.

Mehanna HM, Jain A, Morton RP, Watkinson J, Shaha A. Investigating the thyroid nodule. BMJ. 2009;338:705–709.
DOI: 10.1136/bmj.b733

Jin J, McHenry CR. Thyroid incidentaloma. Best Practice and Research: Clinical Endocrinology and Metabolism. 2012;26(1):83–96.

Shao H, Yu X, Wang C, Wang Q, Guan H. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer. Endocrine. 2014;46(2):285–291.

Muramatsu T. Structure and function of midkine as the basis of its pharmacological effects. Br J Pharmacol. 2014;171:814-26.

Jones DR. Measuring midkine: The utility of midkine as a biomarker in cancer and other diseases. British Journal of Pharmacology. 2014;171:2925–2939.
DOI: 10.1111/bph.12601

Muramatsu T, Kadomatsu K. Midkine: An emerging target of drug development for treatment of multiple diseases. British Journal of Pharmacology. 2014;171:811–813.
DOI: 10.1111/bph.12571

Ruan M, Ji T, Wu Z, Zhou J, Zhang C. Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. Int J Oral Maxillofac Surg. 2007;36:159-64.

Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T, Muramatsu T. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res. 1995;86:655-61.

Maeda S, Shinchi H, Kurahara H, et al. Clinical significance of midkine expression in pancreatic head carcinoma. Br J Cancer. 2007;97:405-11.

Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology. 1999;57:253-7.

Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer. 1994;74:1584-90.

Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, et al. A new family of heparin binding growth/differentiation factors: Increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res. 1993;53:1281-5.

O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The angiogenic factor midkine is expressed in bladder cancer, and over expression correlates with a poor outcome in patients with invasive cancers. Cancer Res. 1996;56:2515-8.

Muramatsu T. Midkine. A heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86:410-25.

Takei Y, Kadomatsu K, Goto T, Muramatsu T. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer. 2006;107:864-73.

Patel HH, Goyal N, Goldenberg D. Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer. Annals of Medicine. 2014;46(6): 409–416.

Sakamoto K, Kadomatsu K. Midkine in the pathology of cancer, neural disease, and inflammation. Pathology International. 2012;62(7):445–455.

Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H, Muramatsu T. Midkine induces the transformation of NIH3T3 cells. British Journal of Cancer. 1997;75(3):354–359.

Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 2012;97(6):2084–2092.

Owada K, Sanjo N, Kobayashi T, et al. Midkine inhibits caspase-dependent apoptosis via the activation of mitogenactivated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. Journal of Neurochemistry. 1999;73(5):2084–2092.

Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M. A receptor-like protein-tyrosine phosphatase PTP

Horiba M, Kadomatsu K, Nakamura E, Muramatsu H, Ikematsu S, Sakuma S, et al. Neointima formation in a restenosis model is suppressed in midkine deficient mice. Journal of Clinical Investigation. 2000;105(4):489–495.

Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, et al. Serum midkine levels are increased in patients with various types of carcinomas. British Journal of Cancer. 2000;83(6):701–706.

Kato M, Maeta H, Kato S, Shinozawa T, Terada T. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Modern Pathology. 2000;13(10):1060–1065.

Meng Z, Tan J, Zhang G, Tian W, Fu Q, Li W, et al. Evaluation of serum midkine as a biomarker in differentiated thyroid cancer. Life Sciences. 2015;130:18–24.

Kadomatsu K, Kishida S, Tsubota S. The heparin-binding growth factor midkine: The biological activities and candidate receptors. Journal of Biochemistry. 2013;153(6):511–521.

Kuzu F, Arpaci D, Unal M, Altas A, Haytaoglu G, Can M, et al. Midkine: A novel biomarker to predict malignancy in patients with nodular thyroid disease. International Journal of Endocrinology; 2016. Available:

Jee YH, Celi FS, Sampson M, David BS, Remaley AT, Kebebew E, et al. Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules. Clinical Endocrinology. 2015;83(6):977–984.

Zhang Y, Meng Z, Zhang M, Tan J, Tian W, He X, et al. Immunohistochemical evaluation of midkine and nuclear factor-kappa B as diagnostic biomarkers for papillary thyroid cancer and synchronous metastasis. Life Sci. 2014;118:39-45.

Jia Q, Meng Z, Xu K, He X, Tan J, Zhang G, et al. Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody. Scientific Reports. 2017;7:43516.
DOI: 10.1038/srep43516

Lorente M, Torres S, Salazar M, Carracedo A, Hernández-Tiedra S, Rodríguez-Fornés F, et al. Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. Cell Death and Differentiation. 2011;18(6):959–973.

Kishida S, Mu P, Miyakawa S, Fujiwara M, Abe T, Sakamoto K, et al. Midkine promotes neuroblastoma through notch2 signaling. Cancer Research. 2013;73(4): 1318–1327.

Choi YW, Kim YH, Lee J, Soh EY, Park TJ, Kim JH. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma. Human Pathology. 2015;46:1557–1565.

Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2013;19:3944–3954.
DOI: 10.1158/1078-0432.CCR-12-3363

Shaheen KY, Abdel-Mageed AI, Safwat E, AlBreedy AM. The value of serum midkine level in diagnosis of hepatocellular carcinoma. International Journal of Hepatology. 2015;146389.
DOI: 10.1155/2015/146389

Krzystek-Korpacka M, Diakowska D, Neubauer K, Gamian A. Circulating midkine in malignant and non-malignant colorectal diseases. Cytokine. 2013;64: 158–164.
DOI: 10.1016/j.cyto.2013.07.008

Shimada H, Nabeya Y, Tagawa M, Okazumi SI, Matsubara H, Kadomatsu K, et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Science. 2003;94:628–632.